The test, named EvoScore START, measures a panel of blood-based protein biomarkers to distinguish between epileptic seizures and other similar events.
The company said it will use the funds to commercialize its proteomic PromarkerD kidney disease test and launch an analytical testing service business.
The Copenhagen-based firm published the first public demonstration of its InBio Map protein interaction tool in a study released this week in Nature Methods.
According to Cedars Sinai Medical Center's Jennifer Van Eyk, mass spec-based proteomics' clinical potential is on the cusp of being realized.
In a recent study, the researchers demonstrated the ability of proteoform-dependent data acquisition software to broaden coverage in top-down experiments.
In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.
Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.
In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.
Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.